바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.58 No.4
Citation Share

Gemcitabine Plus Vinorelbine as Second-line Chemotherapy of the Patients of Previously Treated Non-small Cell lung Cancer: Phase Ⅱ Trial

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2005, v.58 no.4, pp.344-351









& (2005). Gemcitabine Plus Vinorelbine as Second-line Chemotherapy of the Patients of Previously Treated Non-small Cell lung Cancer: Phase Ⅱ Trial. Tuberculosis & Respiratory Diseases, 58(4), 344-351.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background : Both gemcitabine and vinorelbine are effective anticancer drugs with mild toxicity on non-small cell lung cancer, and monotherapy of these drugs are effective as a second-line chemotherapy. The aim of this trial was to assess the response and toxicity of a combination of gemcitabine and vinorelbine in patients of previously treated for non-small cell lung cancer. Materials and Methods : 24 patients, initial stage III A/B,IV and previously treated with platinium and taxane based regimens, were enrolled from June 2000 to March 2004. The regimens consisted of vinorelbine 25mg/m2 followed by an infusion of gemcitabine 1000mg/m2 on day 1 and day 8 every three weeks. This course was repeated more than twice. Results : Twenty-four patients were analyzed for the response, survival rate, and toxicities. The overall response was 17% with a complete remission rate of 4%. The median time-to progression (TTP) was 3.1 months (95%, CI 1-10months), and the survival time was 8.2 months (95%, CI 1-23 months). The grade 3/4 toxicities encountered were neutropenia (12.5%), anemia (0%), thrombocytopenia (0%). Non-hematological 3/4 toxicities were not observed. Conclusion : A combination of gemcitabine and vinorelbine in patients previously treated for non-small cell lung cancer provides a relatively good response rate, and a low toxicity profile. However, further study will be needed to confirm its effectiveness. (Tuberc Respir Dis 2005; 58: 344-351)

keywords
Advanced non-small cell lung cancer, Second-line chemotherapy, Gemcitabine, Vinorelbine

Reference

1.

(2000) Kim GH. Rescent advances in lung cancer chemotherapy. ,

2.

(1991) A phase II study of vinorelbine in the treatment of non-small cell lung cancer,

3.

et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vindesine alone in advanced non-small cell lung cancer. J Clin Oncol 1994,

4.

(1994) A phase II study of vinorelbine,a new derivative of vinca alkaloid,for previously untreated advanced non-small cell lung cancer,

5.

(1999) single agent and combination therapy in non-small cell lung cancer. ,

6.

(1996) Vinorelbine:an overview,

7.

(2000) et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients versus etoposide with cisplatin.,

8.

(1996) Activity of gemci� tabine in patients with non-small cell lung a multicentre, extended phase II study. ,

9.

(2000) Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer,

10.

Rugg TA. Efficacy and safety profile of gemcitabine in non-small cell lung cancer,

11.

(1998) Vinorelbine/gemcitabine in advanced non-small cell lung cancer:a phase I trial,

12.

(1994) Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer,

13.

(1999) et al. Gemcitabine as second- line treatment for advanced non-small cell lung cancer,

14.

(1995) Phase II trial of paclitaxel for treatment of advanced inoperable non- small cell lung cancer,

15.

(2001) et al. Activity of single-agent gemcitabine as seconde-line treatment after previous chemotherapy or radiotherapy in advanced non-small cell lung cancer. , Aaronson N

16.

(1996) Gemcitabine safety overview. ,

17.

(2001) Gemcitabine and vinorelbine as first-line therapy for non-small cell lung cancer:a phase II trial,

18.

(1996) boplatin in inoperable non-small cell lung cancer,

19.

(1995) boplatin in combination in the treatment of non- small cell lung cancer,

20.

(2004) Randomized phase III study of gemcitabine and vinorelbine versus gemcitabin relbine and cisplatin in the treatment of advanced non-small cell lung cancer,

21.

(1999) Gemcitabine as second-line treatment for advanced non-small cell lung cancer:a phase II trial,

22.

(1999) Gemcitabine in platinum treated non-small cell lung cancer,

23.

Failure of vinorelbine to produce responses in prereated non-small cell lung cancer patients,

24.

rmacokinetics of vindesine and of vindesin-cisplatin in previously treated patients with non-small cell lung cancer,

25.

(1999) Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer:report of a phase II trial,

26.

Second-line chemotherapy for resistant the role of taxol,

27.

(1995) Paclitaxel by 1-hour infusion:an active drug in metastatic non-small cell lung cancer,

28.

(2000) Gemcitabine and vinorelbine in the second-line treatment of non- small cell lung carcinoma patients:a minnie pearl cancer research network phase II trial,

29.

(1999) Phase II study of combination weekly gemcitabine and vinorelbine in patients with previously treated non-small cell lung cancer,

30.

(2000) Jaime AB. Second-line treat? ment with gemcitabine and vinorelbine in non-small cell lung cancer cisplatin failures,

31.

(2000) ment with gemcitabine and vinorelbine in non-small cell lung cancer cisplatin failures,

32.

(2001) Gemcitabine and vinorelbine as second-line therapy in non-small cell lung cancer after prior treatment with taxane+pla,

33.

(2003) Phase II study of gemcitabine and vinorelbine combination therapy in patients with non- small cell lung cancer not responding to previous chemotherapy,

34.

(2003) Phase II study of gemcitabine and vinor elbine as second-line chemotherapy in non-small cell lung cancer,

35.

(2004) Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum,

36.

(1999) Second-line treatment with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer,

37.

(1998) Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin or docetaxel-based chemotherapy:a multicenter phase II trial,

38.

(1999) Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer pre-viously treated with platinum- based chemotherapy,

39.

(1996) Pilot study of vin orelbine and paclitaxel in patients with refractory non-small cell lung cancer,

40.

(1999) Second-line chemotherapy with weekly cisplatin and irinotecan in patients with re,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy